MTOR and non-small cell lung carcinoma: Combination of KRASG12D and PI3K-AKT-mTOR pathway inhibition in KRASG12D cells was synergistic, eliciting a cytotoxic response that represents a potential mutant-specific treatment approach for NSCLC.